Literature DB >> 22575637

Charcot-Marie-Tooth disease: emerging mechanisms and therapies.

Constantin d'Ydewalle1, Veronick Benoy, Ludo Van Den Bosch.   

Abstract

Charcot-Marie-Tooth disease is the most common inherited disorder of the peripheral nervous system. The disease is characterized by a progressive muscle weakness and atrophy, sensory loss, foot (and hand) deformities and steppage gait. While many of the genes associated with axonal CMT have been identified, to date it is unknown which mechanism(s) causes the disease. However, genetic findings indicate that the underlying mechanisms mainly converge to the axonal cytoskeleton. In this review, we will summarize the evidence for this pathogenic convergence. Furthermore, recent work with new transgenic mouse models has led to the identification of histone deacetylase 6 as a potential therapeutic target for inherited peripheral neuropathies. This enzyme deacetylates microtubules and plays a crucial role in the regulation of axonal transport. These findings offer new perspectives for a potential therapy to treat axonal Charcot-Marie-Tooth disease and other neurodegenerative disorders characterized by axonal transport defects.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22575637     DOI: 10.1016/j.biocel.2012.04.020

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  10 in total

1.  Peptide mimetic of the S100A4 protein modulates peripheral nerve regeneration and attenuates the progression of neuropathy in myelin protein P0 null mice.

Authors:  Mihai Moldovan; Volodymyr Pinchenko; Oksana Dmytriyeva; Stanislava Pankratova; Kåre Fugleholm; Jorg Klingelhofer; Elisabeth Bock; Vladimir Berezin; Christian Krarup; Darya Kiryushko
Journal:  Mol Med       Date:  2013-04-30       Impact factor: 6.354

Review 2.  The promise and perils of HDAC inhibitors in neurodegeneration.

Authors:  Alessandro Didonna; Puneet Opal
Journal:  Ann Clin Transl Neurol       Date:  2014-12-03       Impact factor: 4.511

3.  A Network Pharmacology Approach for the Identification of Common Mechanisms of Drug-Induced Peripheral Neuropathy.

Authors:  Guillermo de Anda-Jáuregui; Brett A McGregor; Kai Guo; Junguk Hur
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-02-20

4.  PDXK mutations cause polyneuropathy responsive to pyridoxal 5'-phosphate supplementation.

Authors:  Viorica Chelban; Matthew P Wilson; Jodi Warman Chardon; Jana Vandrovcova; M Natalia Zanetti; Eleni Zamba-Papanicolaou; Stephanie Efthymiou; Simon Pope; Maria R Conte; Giancarlo Abis; Yo-Tsen Liu; Eloise Tribollet; Nourelhoda A Haridy; Juan A Botía; Mina Ryten; Paschalis Nicolaou; Anna Minaidou; Kyproula Christodoulou; Kristin D Kernohan; Alison Eaton; Matthew Osmond; Yoko Ito; Pierre Bourque; James E C Jepson; Oscar Bello; Fion Bremner; Carla Cordivari; Mary M Reilly; Martha Foiani; Amanda Heslegrave; Henrik Zetterberg; Simon J R Heales; Nicholas W Wood; James E Rothman; Kym M Boycott; Philippa B Mills; Peter T Clayton; Henry Houlden
Journal:  Ann Neurol       Date:  2019-07-01       Impact factor: 10.422

5.  Structural basis for adhesion G protein-coupled receptor Gpr126 function.

Authors:  Katherine Leon; Rebecca L Cunningham; Joshua A Riback; Ezra Feldman; Jingxian Li; Tobin R Sosnick; Minglei Zhao; Kelly R Monk; Demet Araç
Journal:  Nat Commun       Date:  2020-01-10       Impact factor: 14.919

Review 6.  Ascorbic acid for the treatment of Charcot-Marie-Tooth disease.

Authors:  Burkhard Gess; Jonathan Baets; Peter De Jonghe; Mary M Reilly; Davide Pareyson; Peter Young
Journal:  Cochrane Database Syst Rev       Date:  2015-12-11

Review 7.  The genetics of Charcot-Marie-Tooth disease: current trends and future implications for diagnosis and management.

Authors:  J Chad Hoyle; Michael C Isfort; Jennifer Roggenbuck; W David Arnold
Journal:  Appl Clin Genet       Date:  2015-10-19

8.  Distribution and development of peripheral glial cells in the human fetal cochlea.

Authors:  Heiko Locher; John C M J de Groot; Liesbeth van Iperen; Margriet A Huisman; Johan H M Frijns; Susana M Chuva de Sousa Lopes
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

9.  Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease.

Authors:  Veronick Benoy; Pieter Vanden Berghe; Matthew Jarpe; Philip Van Damme; Wim Robberecht; Ludo Van Den Bosch
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

10.  Disruption of genes associated with Charcot-Marie-Tooth type 2 lead to common behavioural, cellular and molecular defects in Caenorhabditis elegans.

Authors:  Ming S Soh; Xinran Cheng; Tarika Vijayaraghavan; Arwen Vernon; Jie Liu; Brent Neumann
Journal:  PLoS One       Date:  2020-04-15       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.